The new drug approvals of 1993, 1994, and 1995: Trends in drug development

American Journal of Therapeutics

Volumn 4, Issue 1, 1997, Pages 46-54

  Kaitin, Kenneth I ^a   Manocchia, Michael ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Food and Drug Administration; new chemical entities; new drug development; pharmaceutical industry

Indexed keywords

ACARBOSE; ALENDRONIC ACID; AMIFOSTINE; ANASTROZOLE; APROTININ; AZELAIC ACID; BICALUTAMIDE; BUDESONIDE; CALCIPOTRIOL; CARVEDILOL; CETIRIZINE; CISAPRIDE; CLADRIBINE; DALTEPARIN; DIRITHROMYCIN; DORZOLAMIDE; ENOXAPARIN; FAMCICLOVIR; FELBAMATE; FENOFIBRATE; FLUINDOSTATIN; FLUVOXAMINE; FLUVOXAMINE MALEATE; GABAPENTIN; GLIMEPIRIDE; GRANISETRON; IBUTILIDE FUMARATE; MERCAPTAMINE; PROSTACYCLIN; RAZOXANE; UNINDEXED DRUG;

DRUG APPROVAL; DRUG INDUSTRY; DRUG LEGISLATION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; PRIORITY JOURNAL; REVIEW;

EID: 0030947897     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199701000-00010     Document Type: Review

References (30)

1. Kaitin KI, Manocchia M, Seibring M, Lasagna L: The new drug approvals of 1990, 1991, and 1992: Trends in drug development. J Clin Pharmacol 1994;34:120-127.
2. Kaitin KI, DiCerbo PA, Lasagna L: The new drug approvals of 1987, 1988, and 1989: Trends in drug development. J Clin Pharmacol 1991;31:116-122.
3. Kaitin KI, Richard BW, Lasagna L: Trends in drug development: The 1985-86 new drug approvals. J Clin Pharmacol 1987;27:542-548.
4. FDA Performance and Accountability Act of 1995 (S 1477). U.S. Food and Drug Administration.
5. Drug and Biological Products Reform Act of 1996 (HR 3199).
6. Clinton B, Gore A: National Performance Review: Reinventing Government. The White House, Washington DC, 1995.
7. The Patient Is Waiting. Pharmaceutical Research and Manufacturers of America, Washington DC, May 1996.
8. FDA Regulatory Reform: A Proposal by the Biotechnology Industry Organization. Concept Paper: 2/27/95. BIO, Washington DC, 1995.
9. Clinton B, Gore A: Reinventing the Regulation of Cancer Drugs. The White House, Washington DC, March 29, 1996.
10. Prescription Drug User Fee Act of 1992. Pub Law 102-571 (1992 Oct 29); 21 USC 379; 106 Stat 4491.
11. FDA Drug Approval: Review Time Has Decreased in Recent Years. (GAO/PMED-96-1) U.S. General Accounting Office, Washington DC, Oct 1995.
12. Third Annual Performance Report: Prescription Drug User Fee Act of 1992: Fiscal Year 1995 Report to Congress. U.S. Food and Drug Administration, Rockville, MD, Dec 1995.
13. Shulman SR, Kaitin KI: The Prescription Drug User Fee Act of 1992: A five-year experiment for industry and the FDA. Pharmacol Econ 1996;9:121-133.
14. Kaitin KI, Bryant NR, Lasagna L: The role of the research-based pharmaceutical industry in medical progress in the United States. J Clin Pharmacol 1993;33:412-417.
15. DiMasi JA: A new look at U.S. drug development and approval times. Am J Therapeutics. In press.
16. Kaitin KI: FDA reform: Setting the stage for efforts to reform the Agency. Drug Inf J. 1997;31:27-33.
17. DiMasi JA, Seibring MA, Lasagna L: New drug development in the United States 1963 to 1992. Clin Pharmacol Ther 1994;55:609-622.
18. Accelerated approval of new drugs for serious or life-threatening illnesses. 21 CFR 314.500.
19. Accelerated approval of biological products for serious or life-threatening illnesses. 21 CFR 601.40.
20. Shulman SR, Brown JS: The Food and Drug Administration's early access and fast-track approval initiatives: How have they worked? Food Drug Law 1995;50:503-532.
21. Kaitin KI, Walsh HL, Lasagna L: Are initiatives to speed the new drug approval process working? Drug Inf J 1992;26:341-349.
22. Meyer GF: Keynote address. CANDAs Conference 1993, Amsterdam, April 19, 1993.
23. US FDA to automate all NDAs by 1995. Scrip 1991;1641: 17.
24. Second Annual Performance Report: Prescription Drug User Fee Act of 1992: Fiscal Year 1994 Report to Congress. Food and Drug Administration, Rockville, MD, Dec 1994.
25. Kaitin KI, Brown JS: A drug lag update. In White paper on four areas of relevance to new drug development and review in the United States. Drug Inf J 1995;29:361-373.
26. Kaitin KI, Mattison N, Northington FK, Lasagna L: The drug lag: An update of new drug introductions in the United States and the United Kingdom, 1977 through 1987. Clin Pharmacol Ther 1989;46:121-138.
27. Wardell WM: Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison. Clin Pharmacol Ther 1973;14:773-790.
28. Kessler DA: Remarks at the Food and Drug Law Institute Annual Meeting, Washington DC, December 12, 1995
29. and Kessler DA, Haas AE, Fieden KL, et al.: America's rapid access to new drugs: an international comparison. J Am Med Assoc. In press.
30. Kaitin KI: Statement. Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives. The Need for FDA Reform. February 27, 1996. 104th Congress 2d Session:81-7,100-1,185-94.